1
|
Martínez-Cignoni MR, González-Vicens A, Morán-Costoya A, Amengual-Cladera E, Gianotti M, Valle A, Proenza AM, Lladó I. Diabesity alters the protective effects of estrogens on endothelial function through adipose tissue secretome. Free Radic Biol Med 2024:S0891-5849(24)00639-7. [PMID: 39241985 DOI: 10.1016/j.freeradbiomed.2024.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2024] [Revised: 09/02/2024] [Accepted: 09/03/2024] [Indexed: 09/09/2024]
Abstract
Estrogens have a well-known protective role in the development of the metabolic syndrome. Nevertheless, recent epidemiological data question the cardioprotective effect of estrogens in obese and diabetic women. In this context, white adipose tissue (WAT) becomes dysfunctional, which has an impact on the cardiovascular system. The aim of the study was to elucidate the role of 17β-estradiol (E2) in the interplay between adipose tissue and endothelial function in an animal model of diabesity. We used ZDF (fa/fa) female rats subjected to ovariectomy (OVA), OVA+E2 or sham operated, as well as non-obese non-diabetic ZDF (fa/+) rats. Endothelial function and vascular remodeling markers were assessed in the aorta, while mitochondrial function, oxidative stress, and adiponectin production were analyzed in gonadal WAT. Conditioned media from gonadal WAT explants were used to assess the effects of WAT secretome on HUVEC. Additionally, the adiponectin receptor agonist AdipoRON and E2 were utilized to examine potential interactions. Ovariectomy ameliorated the WAT dysfunction associated to the obese and diabetic state and promoted adiponectin secretion, effects that were linked to a reduction of endothelial dysfunction and inflammatory markers in the aorta of OVA rats and in HUVEC treated with OVA-conditioned media. Our findings provide evidence supporting the idea that in the context of obesity and diabetes, ovariectomy improves WAT secretome and positively impacts endothelial function, suggesting a detrimental role for E2. Additionally, our results point to adiponectin as the primary driver of the effects exerted by ovariectomy on the adipovascular axis.
Collapse
Affiliation(s)
- Melanie Raquel Martínez-Cignoni
- Grup de Metabolisme Energètic i Nutrició (GMEIN), Departament de Biologia Fonamental i Ciències de la Salut, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Baleares, Ctra. Valldemossa, km 7.5, E-07122 Palma, Balearic Islands, Spain
| | - Agustí González-Vicens
- Grup de Metabolisme Energètic i Nutrició (GMEIN), Departament de Biologia Fonamental i Ciències de la Salut, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Baleares, Ctra. Valldemossa, km 7.5, E-07122 Palma, Balearic Islands, Spain
| | - Andrea Morán-Costoya
- Grup de Metabolisme Energètic i Nutrició (GMEIN), Departament de Biologia Fonamental i Ciències de la Salut, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Baleares, Ctra. Valldemossa, km 7.5, E-07122 Palma, Balearic Islands, Spain; Institut d'Investigació Sanitària de les Illes Baleares (IdISBa), Hospital Universitari Son Espases, E-07120 Palma, Balearic Islands, Spain
| | - Emilia Amengual-Cladera
- Grup de Metabolisme Energètic i Nutrició (GMEIN), Departament de Biologia Fonamental i Ciències de la Salut, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Baleares, Ctra. Valldemossa, km 7.5, E-07122 Palma, Balearic Islands, Spain; Institut d'Investigació Sanitària de les Illes Baleares (IdISBa), Hospital Universitari Son Espases, E-07120 Palma, Balearic Islands, Spain
| | - Magdalena Gianotti
- Grup de Metabolisme Energètic i Nutrició (GMEIN), Departament de Biologia Fonamental i Ciències de la Salut, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Baleares, Ctra. Valldemossa, km 7.5, E-07122 Palma, Balearic Islands, Spain
| | - Adamo Valle
- Grup de Metabolisme Energètic i Nutrició (GMEIN), Departament de Biologia Fonamental i Ciències de la Salut, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Baleares, Ctra. Valldemossa, km 7.5, E-07122 Palma, Balearic Islands, Spain; Institut d'Investigació Sanitària de les Illes Baleares (IdISBa), Hospital Universitari Son Espases, E-07120 Palma, Balearic Islands, Spain; Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/0043), Instituto de Salud Carlos III, E- 28029, Madrid, Spain
| | - Ana María Proenza
- Grup de Metabolisme Energètic i Nutrició (GMEIN), Departament de Biologia Fonamental i Ciències de la Salut, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Baleares, Ctra. Valldemossa, km 7.5, E-07122 Palma, Balearic Islands, Spain; Institut d'Investigació Sanitària de les Illes Baleares (IdISBa), Hospital Universitari Son Espases, E-07120 Palma, Balearic Islands, Spain; Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/0043), Instituto de Salud Carlos III, E- 28029, Madrid, Spain.
| | - Isabel Lladó
- Grup de Metabolisme Energètic i Nutrició (GMEIN), Departament de Biologia Fonamental i Ciències de la Salut, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Baleares, Ctra. Valldemossa, km 7.5, E-07122 Palma, Balearic Islands, Spain; Institut d'Investigació Sanitària de les Illes Baleares (IdISBa), Hospital Universitari Son Espases, E-07120 Palma, Balearic Islands, Spain; Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/0043), Instituto de Salud Carlos III, E- 28029, Madrid, Spain
| |
Collapse
|
2
|
Wu C, Li X, Zhao H, Ling Y, Ying Y, He Y, Zhang S, Liang S, Wei J, Gan X. Resistance exercise promotes the resolution and recanalization of deep venous thrombosis in a mouse model via SIRT1 upregulation. BMC Cardiovasc Disord 2023; 23:18. [PMID: 36639616 PMCID: PMC9837998 DOI: 10.1186/s12872-022-02908-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Accepted: 10/19/2022] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND Early exercise for acute deep venous thrombosis (DVT) improves the patient's symptoms and does not increase the risk of pulmonary embolism. However, information about its effect on thrombus resolution is limited. The aim of this study was to investigate the role of resistance exercise (RE) in thrombus resolution and recanalization and determine its underlying mechanisms. METHODS: Ninety-six C57BL/6 J mice were randomly divided into four groups: Control group (C, n = 24); DVT group (D, n = 24); RE + DVT group (ED, n = 24); and inhibitor + RE + DVT group (IED, n = 24). A DVT model was induced by stenosis of the inferior vena cava (IVC). After undergoing IVC ultrasound within 24 h post-operation to confirm DVT formation, mice without thrombosis were excluded. Other mice were sacrificed and specimens were obtained 14 or 28 days after operation. Thrombus-containing IVC was weighed, and the thrombus area and recanalization rate were calculated using HE staining. Masson's trichrome staining was used to analyze the collagen content. RT-PCR and ELISA were performed to examine IL-6, TNF-α, IL-10, and VEGF expression levels. SIRT1 expression was assessed using immunohistochemistry staining and RT-PCR. VEGF-A protein expression and CD-31-positive microvascular density (MVD) in the thrombus were observed using immunohistochemistry. RESULTS: RE did not increase the incidence of pulmonary embolism. It reduced the weight and size of the thrombus and the collagen content. Conversely, it increased the recanalization rate. It also decreased the levels of the pro-inflammatory factors IL-6 and TNF-α and increased the expression levels of the anti-inflammatory factor IL-10. RE enhanced VEGF and SIRT1 expression levels and increased the MVD in the thrombosis area. After EX527 (SIRT1 inhibitor) was applied, the positive effects of exercise were suppressed. CONCLUSIONS RE can inhibit inflammatory responses, reduce collagen deposition, and increase angiogenesis in DVT mice, thereby promoting thrombus resolution and recanalization. Its underlying mechanism may be associated with the upregulation of SIRT1 expression.
Collapse
Affiliation(s)
- Caijiao Wu
- grid.412594.f0000 0004 1757 2961Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021 Guangxi China
| | - Xiaorong Li
- grid.412594.f0000 0004 1757 2961Department of Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi China
| | - Huihan Zhao
- grid.412594.f0000 0004 1757 2961Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021 Guangxi China
| | - Ying Ling
- grid.412594.f0000 0004 1757 2961Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021 Guangxi China
| | - Yanping Ying
- grid.412594.f0000 0004 1757 2961Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021 Guangxi China
| | - Yu He
- grid.412594.f0000 0004 1757 2961Medical Lab, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021 Guangxi China
| | - Shaohan Zhang
- grid.412594.f0000 0004 1757 2961Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021 Guangxi China
| | - Shijing Liang
- grid.412594.f0000 0004 1757 2961Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021 Guangxi China
| | - Jiani Wei
- grid.412594.f0000 0004 1757 2961Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021 Guangxi China
| | - Xiao Gan
- grid.412594.f0000 0004 1757 2961Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021 Guangxi China
| |
Collapse
|
3
|
Gammoh O, AlQudah A, Rob OAA, Hmedat A, Kifaieh A, Weshah F, Ennab W, Qnais E. Modulation of salivary ICAM-1 and SIRT1 by disease modifying drugs in undepressed relapsing-remitting multiple sclerosis patients. Mult Scler Relat Disord 2022; 68:104257. [PMID: 36308972 DOI: 10.1016/j.msard.2022.104257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 10/15/2022] [Accepted: 10/18/2022] [Indexed: 11/27/2022]
Abstract
BACKGROUND The pathophysiology of Multiple Sclerosis (MS) is multifactorial where the correlation between inflammation and MS is evident. Adhesion molecules such as Intercellular adhesion molecule-1 (ICAM-1) are implicated in MS. SIRT1 is a member of surtins family that play a protective role in neurodegenerative and inflammatory diseases. Although previously studied in Relapsing-Remitting Multiple Sclerosis (RRMS) patients, however the salivary expression of ICAM-1 and SIRT1 have not been yet studied in patients receiving fingolimod or interferon-β. Therefore, the present research aimed to investigate the expression of salivary ICAM-1 and SIRT1 in RRMS patients treated with fingolimod or interferon-β compared to controls. METHODS RRMS patients attending the neurology department of AL-Bashir Hospital were recruited. Patients' demographics, clinical information, and psychiatric status were evaluated (depression, anxiety and stress). Afterward, matched controls were recruited, then unstimulated whole saliva was obtained from the participants. The salivary expression of ICAM-1 and SIRT1 was investigated using western blot and normalized with β-actin. RESULTS Data were analyzed from 53 participants: 26 on fingolimod, 14 on interferon-β, and 13 control. The interferon-β treated patients showed a significantly (p < 0.001) higher ICAM-1 expression and lower SIRT1 expression (p < 0.05) compared to the control. Levels of ICAM-1 and SIRT1 did not vary between fingolimod and control. CONCLUSION ICAM-1 and SIRT1 expression might be affected with fingolimod or INF- β treatment which should be investigated more in the future.
Collapse
Affiliation(s)
- Omar Gammoh
- Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
| | - Abdelrahim AlQudah
- Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, the Hashemite University, Zarqa 13133, Jordan
| | - Osama Abo Al Rob
- Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan
| | - Ali Hmedat
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan
| | - Ahlam Kifaieh
- Department of Pharmacy Istishari Hospital, Amman, Jordan
| | - Feras Weshah
- Department of Neurology, Al-Bashir Hospital, Amman 11151, Jordan
| | - Wail Ennab
- Department of Neurology, Al-Bashir Hospital, Amman 11151, Jordan
| | - Esam Qnais
- Department of Biological Sciences, Faculty of Science, the Hashemite University, Zarqa 13133, Jordan
| |
Collapse
|
4
|
Sipka A, Babasyan S, Mann S, Freer H, Klaessig S, Wagner B. Development of monoclonal antibodies for quantification of bovine tumor necrosis factor-α. JDS COMMUNICATIONS 2021; 2:415-420. [PMID: 36337098 PMCID: PMC9623662 DOI: 10.3168/jdsc.2021-0123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Accepted: 08/23/2021] [Indexed: 06/16/2023]
Abstract
The expression of the proinflammatory cytokine tumor necrosis factor-α (TNF-α) is associated with production losses in dairy cows and is a hallmark of early inflammatory processes. Reliable tools for the detection and quantification of soluble as well as cytoplasmatic bovine TNF-α are needed to deepen our understanding of inflammatory dynamics in dairy cows. The objective of this study was to generate a monoclonal antibody (mAb) pair that could be used to quantify bovine TNF-α in cell culture supernatants and plasma and to detect cytoplasmatic TNF-α in bovine leukocyte populations. One mouse was immunized with a recombinant fusion protein of bovine TNF-α and equine IL-4 generated in Chinese hamster ovary cells. Murine monoclonal antibodies specific to bovine TNF-α were produced in hybridoma cell lines and selected based on their specificity to the recombinant IL-4/TNF-α protein. Clones 197-1 and 65-2, both murine IgG1 isotypes, detected the bovine TNF-α fusion protein as well as the native protein produced by peripheral blood mononuclear cells (PBMC) stimulated with a combination of phorbol myristate acetate and ionomycin. Both mAbs were tested for and lacked cross-reactivity to equine IL-4 and 3 other recombinant bovine cytokines (IFN-γ, IL-10, and CCL5) and were used to develop a fluorescent bead-based assay. The range of bovine TNF-α detection in the assay was 0.2 to 620 ng/mL, and the test was used to quantify native bovine TNF-α in cell culture supernatants of stimulated PBMC and in plasma from ex vivo whole-blood stimulations. Sample matrices were spiked with TNF-α, with subsequent recovery rates (mean ± SD) of 89% ± 9 (n = 3) in culture medium and 94% ± 12 (n = 3) in heat-inactivated fetal bovine serum. Serial dilutions of plasma and cell culture supernatants from stimulated whole blood or PBMC indicated excellent accuracy for quantification of native TNF-α in bovine samples. Both bovine TNF-α mAbs also detected intracellular TNF-α in bovine CD14+ monocytes and CD4+/CD8+ lymphocytes. In conclusion, we demonstrated that the mAbs generated provide valuable new tools to quantify native bovine TNF-α in a wide concentration range and to characterize intracellular TNF-α expression in bovine leukocytes.
Collapse
|
5
|
Liu L, Fan L, Chan M, Kraakman MJ, Yang J, Fan Y, Aaron N, Wan Q, Carrillo-Sepulveda MA, Tall AR, Tabas I, Accili D, Qiang L. PPARγ Deacetylation Confers the Antiatherogenic Effect and Improves Endothelial Function in Diabetes Treatment. Diabetes 2020; 69:1793-1803. [PMID: 32409492 PMCID: PMC7372079 DOI: 10.2337/db20-0217] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Accepted: 05/11/2020] [Indexed: 12/18/2022]
Abstract
Cardiovascular disease (CVD) is the leading cause of death in patients with diabetes, and tight glycemic control fails to reduce the risk of developing CVD. Thiazolidinediones (TZDs), a class of peroxisome proliferator-activated receptor γ (PPARγ) agonists, are potent insulin sensitizers with antiatherogenic properties, but their clinical use is limited by side effects. PPARγ deacetylation on two lysine residues (K268 and K293) induces brown remodeling of white adipose tissue and uncouples the adverse effects of TZDs from insulin sensitization. Here we show that PPARγ deacetylation confers antiatherogenic properties and retains the insulin-sensitizing effects of TZD while circumventing its detriments. We generated mice homozygous with mice with deacetylation-mimetic PPARγ mutations K268R/K293R (2KR) on an LDL-receptor knockout (Ldlr -/- ) background. 2KR:Ldlr -/- mice showed smaller atherosclerotic lesion areas than Ldlr -/- mice, particularly in aortic arches. With rosiglitazone treatment, 2KR:Ldlr -/- mice demonstrated a residual antiatherogenic response and substantial protection against bone loss and fluid retention. The antiatherosclerotic effect of 2KR was attributed to the protection of endothelium, indicated by improved endothelium-dependent vasorelaxation and repressed expression of proatherogenic factors including inducible nitric oxide synthase, interleukin-6, and NADPH oxidase 2. Therefore, manipulating PPARγ acetylation is a promising therapeutic strategy to control risk of CVD in diabetes treatment.
Collapse
Affiliation(s)
- Longhua Liu
- Naomi Berrie Diabetes Center, Columbia University, New York, NY
- Department of Pathology and Cell Biology, Columbia University, New York, NY
| | - Lihong Fan
- Naomi Berrie Diabetes Center, Columbia University, New York, NY
- Department of Pathology and Cell Biology, Columbia University, New York, NY
- Department of Cardiology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shanxi, China
| | - Michelle Chan
- Department of Biological Sciences, Columbia University, New York, NY
| | - Michael J Kraakman
- Naomi Berrie Diabetes Center, Columbia University, New York, NY
- Department of Medicine, Columbia University, New York, NY
| | - Jing Yang
- Naomi Berrie Diabetes Center, Columbia University, New York, NY
- Department of Pathology and Cell Biology, Columbia University, New York, NY
- Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shanxi, China
| | - Yong Fan
- Naomi Berrie Diabetes Center, Columbia University, New York, NY
- Department of Pathology and Cell Biology, Columbia University, New York, NY
| | - Nicole Aaron
- Naomi Berrie Diabetes Center, Columbia University, New York, NY
- Department of Pharmacology, Columbia University, New York, NY
| | - Qianfen Wan
- Naomi Berrie Diabetes Center, Columbia University, New York, NY
- Department of Pathology and Cell Biology, Columbia University, New York, NY
| | | | - Alan R Tall
- Department of Medicine, Columbia University, New York, NY
| | - Ira Tabas
- Department of Medicine, Columbia University, New York, NY
| | - Domenico Accili
- Naomi Berrie Diabetes Center, Columbia University, New York, NY
- Department of Medicine, Columbia University, New York, NY
| | - Li Qiang
- Naomi Berrie Diabetes Center, Columbia University, New York, NY
- Department of Pathology and Cell Biology, Columbia University, New York, NY
| |
Collapse
|
6
|
Zhang Y, Cui G, Wang Y, Gong Y, Wang Y. SIRT1 activation alleviates brain microvascular endothelial dysfunction in peroxisomal disorders. Int J Mol Med 2019; 44:995-1005. [PMID: 31257461 PMCID: PMC6657955 DOI: 10.3892/ijmm.2019.4250] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 06/11/2019] [Indexed: 02/03/2023] Open
Abstract
Peroxisomal disorders are genetically heterogeneous metabolic disorders associated with a deficit of very long chain fatty acid β-oxidation that commonly manifest as early-onset neurodegeneration. Brain microvascular endothelial dysfunction with increased permeability to monocytes has been described in X-linked adrenoleukodystrophy, one of the most common peroxisomal disorders caused by mutations of the ATP binding cassette subfamily D member 1 (ABCD1) gene. The present study demonstrated that dysregulation of sirtuin 1 (SIRT1) in human brain microvascular endothelial cells (HBMECs) mediates changes in adhesion molecules and tight-junction protein expression, as well as increased adhesion to monocytes associated with peroxisomal dysfunction due to ABCD1 or hydroxysteroid 17-β dehydrogenase 4 silencing. Furthermore, enhancement of the function of SIRT1 by resve-ratrol attenuated this molecular and functional dysregulation of HBMECs via modulation of the nuclear factor-κB and Krüppel-like factor 4 signaling pathways.
Collapse
Affiliation(s)
- Yunshan Zhang
- Department of Anatomy and Embryology, Xuzhou Key Laboratory of Neurobiology, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China
| | - Guiyun Cui
- Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China
| | - Yue Wang
- Department of Neurobiology and Anatomy, Xuzhou Key Laboratory of Neurobiology, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China
| | - Yi Gong
- Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China
| | - Yulan Wang
- Department of Anatomy and Embryology, Xuzhou Key Laboratory of Neurobiology, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China
| |
Collapse
|
7
|
Du C, Lin X, Xu W, Zheng F, Cai J, Yang J, Cui Q, Tang C, Cai J, Xu G, Geng B. Sulfhydrated Sirtuin-1 Increasing Its Deacetylation Activity Is an Essential Epigenetics Mechanism of Anti-Atherogenesis by Hydrogen Sulfide. Antioxid Redox Signal 2019; 30:184-197. [PMID: 29343087 DOI: 10.1089/ars.2017.7195] [Citation(s) in RCA: 77] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Aims: Hydrogen sulfide (H2S) has a protective role in the pathogenesis of atherosclerosis by multiple pathways. Sirtuin-1 (SIRT1) is a histone deacetylase, as an essential mediated longevity gene, and has an anti-atherogenic effect by regulating the acetylation of some functional proteins. Whether SIRT1 is involved in protecting H2S in atherosclerosis and its mechanism remains unclear. Results: In ApoE-knockout atherosclerosis mice, treatment with an H2S donor (NaHS or GYY4137) reduced atherosclerotic plaque area, macrophage infiltration, aortic inflammation, and plasma lipid level. H2S treatment increased aorta and liver SIRT1 mRNA expression. Overexpression or slicing cystathionine gamma lyase (CSE) also changed intracellular SIRT1 expression. CSE/H2S treatment increased SIRT1 deacetylation in endothelium and hepatocytes and macrophages, then induced deacetylation of its target proteins (P53, P65, and sterol response element binding protein), thereby reducing endothelial and macrophage inflammation and inhibiting macrophage cholesterol uptake and cholesterol de novo synthesis of liver. Also, CSE/H2S induced SIRT1 sulfhydration at its two zinc finger domains, increased its zinc ion binding activity to stabilize the alpha-helix structure, lowered its ubiquitination, and reduced its degradation. Innovation: H2S is a novel SIRT1 activator by direct sulfhydration. Because SIRT1 has a role in longevity, H2S may be a protector for aging-related diseases. Conclusion: Endogenous CSE/H2S directly sulfhydrated SIRT1, enhanced SIRT1 binding to zinc ion, then promoted its deacetylation activity, and increased SIRT1 stability, thus reducing atherosclerotic plaque formation.
Collapse
Affiliation(s)
- Congkuo Du
- 1 MOE Key Lab of Cardiovascular Sciences, Department of Physiology and Pathophysiology, Department of Biomedical Informatics, Center for Noncoding RNA Medicine, School of Basic Medical Science, Peking University Health Science Center. Beijing , People's Republic of China
| | - Xianjuan Lin
- 1 MOE Key Lab of Cardiovascular Sciences, Department of Physiology and Pathophysiology, Department of Biomedical Informatics, Center for Noncoding RNA Medicine, School of Basic Medical Science, Peking University Health Science Center. Beijing , People's Republic of China
| | - Wenjing Xu
- 1 MOE Key Lab of Cardiovascular Sciences, Department of Physiology and Pathophysiology, Department of Biomedical Informatics, Center for Noncoding RNA Medicine, School of Basic Medical Science, Peking University Health Science Center. Beijing , People's Republic of China
| | - Fengjiao Zheng
- 1 MOE Key Lab of Cardiovascular Sciences, Department of Physiology and Pathophysiology, Department of Biomedical Informatics, Center for Noncoding RNA Medicine, School of Basic Medical Science, Peking University Health Science Center. Beijing , People's Republic of China
| | - Junyan Cai
- 1 MOE Key Lab of Cardiovascular Sciences, Department of Physiology and Pathophysiology, Department of Biomedical Informatics, Center for Noncoding RNA Medicine, School of Basic Medical Science, Peking University Health Science Center. Beijing , People's Republic of China
| | - Jichun Yang
- 1 MOE Key Lab of Cardiovascular Sciences, Department of Physiology and Pathophysiology, Department of Biomedical Informatics, Center for Noncoding RNA Medicine, School of Basic Medical Science, Peking University Health Science Center. Beijing , People's Republic of China
| | - Qinghua Cui
- 1 MOE Key Lab of Cardiovascular Sciences, Department of Physiology and Pathophysiology, Department of Biomedical Informatics, Center for Noncoding RNA Medicine, School of Basic Medical Science, Peking University Health Science Center. Beijing , People's Republic of China
| | - Chaoshu Tang
- 1 MOE Key Lab of Cardiovascular Sciences, Department of Physiology and Pathophysiology, Department of Biomedical Informatics, Center for Noncoding RNA Medicine, School of Basic Medical Science, Peking University Health Science Center. Beijing , People's Republic of China
| | - Jun Cai
- 2 State Key Laboratory of Cardiovascular Disease, Hypertension Center , Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
| | - Guoheng Xu
- 1 MOE Key Lab of Cardiovascular Sciences, Department of Physiology and Pathophysiology, Department of Biomedical Informatics, Center for Noncoding RNA Medicine, School of Basic Medical Science, Peking University Health Science Center. Beijing , People's Republic of China
| | - Bin Geng
- 1 MOE Key Lab of Cardiovascular Sciences, Department of Physiology and Pathophysiology, Department of Biomedical Informatics, Center for Noncoding RNA Medicine, School of Basic Medical Science, Peking University Health Science Center. Beijing , People's Republic of China .,2 State Key Laboratory of Cardiovascular Disease, Hypertension Center , Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
| |
Collapse
|
8
|
Hung CH, Chan SH, Chu PM, Lin HC, Tsai KL. Metformin regulates oxLDL-facilitated endothelial dysfunction by modulation of SIRT1 through repressing LOX-1-modulated oxidative signaling. Oncotarget 2017; 7:10773-87. [PMID: 26885898 PMCID: PMC4905438 DOI: 10.18632/oncotarget.7387] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2016] [Accepted: 01/31/2016] [Indexed: 12/20/2022] Open
Abstract
It is suggested that oxLDL is decisive in the initiation and development of atherosclerotic injuries. The up-regulation of oxidative stress and the generation of ROS act as key modulators in developing pro-atherosclerotic and anti-atherosclerotic processes in the human endothelial wall. In this present study, we confirmed that metformin enhanced SIRT1 and AMPK expression in human umbilical vein endothelial cells (HUVECs). Metformin also inhibited oxLDL-increased LOX-1 expression and oxLDL-collapsed AKT/eNOS levels. However, silencing SIRT1 and AMPK diminished the protective function of metformin against oxidative injuries. These results provide a new insight regarding the possible molecular mechanisms of metformin.
Collapse
Affiliation(s)
- Ching-Hsia Hung
- Department of Physical Therapy, College of Medicine, National Cheng Kung University,Tainan, Taiwan.,Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Shih-Hung Chan
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Pei-Ming Chu
- Department of Anatomy, School of Medicine, China Medical University, Taichung, Taiwan
| | - Huei-Chen Lin
- Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.,Department of Physical Therapy, Shu-Zen Junior College of Medicine and Management, Taiwan
| | - Kun-Ling Tsai
- Department of Physical Therapy, College of Medicine, National Cheng Kung University,Tainan, Taiwan
| |
Collapse
|
9
|
Chan SH, Hung CH, Shih JY, Chu PM, Cheng YH, Lin HC, Tsai KL. SIRT1 inhibition causes oxidative stress and inflammation in patients with coronary artery disease. Redox Biol 2017; 13:301-309. [PMID: 28601780 PMCID: PMC5466584 DOI: 10.1016/j.redox.2017.05.027] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2017] [Accepted: 05/31/2017] [Indexed: 01/22/2023] Open
Abstract
Coronary artery disease (CAD) is the primary critical cardiovascular event. Endothelial cell and monocyte dysfunction with subsequent extravagant inflammation are the main causes of vessel damage in CAD. Thus, strategies that repress cell death and manage unsuitable pro-inflammatory responses in CAD are potential therapeutic strategies for improving the clinical prognosis of patients with CAD. SIRT1 (Sirtuin 1) plays an important role in regulating cellular physiological processes. SIRT1 is also thought to protect the cardiovascular system by means of its antioxidant, anti-inflammation and anti-apoptosis activities. In the present study, we found that the SIRT1 expression levels were repressed and the acetylated p53 expression levels were enhanced in the monocytes of patients with CAD. LOX-1/oxidative stress was also up-regulated in the monocytes of patients with CAD, thereby increasing pro-apoptotic events and pro-inflammatory responses. We also demonstrated that monocytes from CAD patients caused endothelial adhesion molecule activation and the adherence of monocytes and endothelial cells. Our findings may explain why CAD patients remain at an increased risk of long-term recurrent ischemic events and provide new knowledge regarding the management of clinical CAD patients.
Collapse
Affiliation(s)
- Shih-Hung Chan
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Ching-Hsia Hung
- Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Jhih-Yuan Shih
- Department of Internal Medicine, Chi-Mei Hospital, Tainan, Taiwan
| | - Pei-Ming Chu
- Department of Anatomy, School of Medicine, China Medical University, Taichung, Taiwan
| | - Yung-Hsin Cheng
- Department of Education and Research, Taipei City Hospital, Taipei, Taiwan
| | - Huei-Chen Lin
- Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Physical Therapy, Shu-Zen Junior College of Medicine and Management, Taiwan
| | - Kun-Ling Tsai
- Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
| |
Collapse
|
10
|
Sirt1-Sirt3 axis regulates human blood-brain barrier permeability in response to ischemia. Redox Biol 2017; 14:229-236. [PMID: 28965081 PMCID: PMC5633840 DOI: 10.1016/j.redox.2017.09.016] [Citation(s) in RCA: 98] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 09/12/2017] [Accepted: 09/21/2017] [Indexed: 12/22/2022] Open
Abstract
Sirtuin1 (Sirt1) and Sirtuin3 (Sirt3) are two well-characterized members of the silent information regulator 2 (Sir2) family of proteins. Both Sirt1 and Sirt3 have been shown to play vital roles in resistance to cellular stress, but the interaction between these two sirtuins has not been fully determined. In this study, we investigated the role of Sirt1-Sirt3 axis in blood-brain barrier (BBB) permeability after ischemia in vitro. Human brain microvascular endothelial cells and astrocytes were co-cultured to model the BBB in vitro and oxygen and glucose deprivation (OGD) was performed to mimic ischemia. The results of transepithelial electrical resistance (TEER) showed that suppression of Sirt1 via siRNA or salermide significantly decreased BBB permeability, whereas Sirt3 knockdown increased BBB permeability. In addition, Sirt1 was shown to regulate Sirt3 expression after OGD through inhibiting the AMPK-PGC1 pathway. Application of the AMPK inhibitor compound C partially prevented the effects of Sirt1-Sirt3 axis on BBB permeability after OGD. The results of flow cytometry and cytochrome c release demonstrated that Sirt1 and Sirt3 exert opposite effects on OGD-induced apoptosis. Furthermore, suppression of Sirt1 was shown to attenuate mitochondrial reactive oxygen species (ROS) generation, which contribute to the Sirt1-Sirt3 axis-induced regulation of BBB permeability and cell damage. In summary, these findings demonstrate that the Sirt1-Sirt3 axis might act as an important modulator in BBB physiology, and could be a therapeutic target for ischemic stroke via regulating mitochondrial ROS generation.
Collapse
|
11
|
Sarumaru M, Watanabe M, Inoue N, Hisamoto Y, Morita E, Arakawa Y, Hidaka Y, Iwatani Y. Association between functional SIRT1 polymorphisms and the clinical characteristics of patients with autoimmune thyroid disease. Autoimmunity 2016; 49:329-37. [DOI: 10.3109/08916934.2015.1134506] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Mika Sarumaru
- Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan and
| | - Mikio Watanabe
- Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan and
| | - Naoya Inoue
- Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan and
| | - Yuko Hisamoto
- Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan and
| | - Emi Morita
- Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan and
| | - Yuya Arakawa
- Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan and
| | - Yoh Hidaka
- Laboratory for Clinical Investigation, Osaka University Hospital, Osaka, Japan
| | - Yoshinori Iwatani
- Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan and
| |
Collapse
|
12
|
Yin Y, Li X, Sha X, Xi H, Li YF, Shao Y, Mai J, Virtue A, Lopez-Pastrana J, Meng S, Tilley DG, Monroy MA, Choi ET, Thomas CJ, Jiang X, Wang H, Yang XF. Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. Arterioscler Thromb Vasc Biol 2015; 35:804-16. [PMID: 25705917 DOI: 10.1161/atvbaha.115.305282] [Citation(s) in RCA: 159] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
OBJECTIVE The role of receptors for endogenous metabolic danger signals-associated molecular patterns has been characterized recently as bridging innate immune sensory systems for danger signals-associated molecular patterns to initiation of inflammation in bone marrow-derived cells, such as macrophages. However, it remains unknown whether endothelial cells (ECs), the cell type with the largest numbers and the first vessel cell type exposed to circulating danger signals-associated molecular patterns in the blood, can sense hyperlipidemia. This report determined whether caspase-1 plays a role in ECs in sensing hyperlipidemia and promoting EC activation. APPROACH AND RESULTS Using biochemical, immunologic, pathological, and bone marrow transplantation methods together with the generation of new apoplipoprotein E (ApoE)(-/-)/caspase-1(-/-) double knockout mice, we made the following observations: (1) early hyperlipidemia induced caspase-1 activation in ApoE(-/-) mouse aorta; (2) caspase-1(-/-)/ApoE(-/-) mice attenuated early atherosclerosis; (3) caspase-1(-/-)/ApoE(-/-) mice had decreased aortic expression of proinflammatory cytokines and attenuated aortic monocyte recruitment; and (4) caspase-1(-/-)/ApoE(-/-) mice had decreased EC activation, including reduced adhesion molecule expression and cytokine secretion. Mechanistically, oxidized lipids activated caspase-1 and promoted pyroptosis in ECs by a reactive oxygen species mechanism. Caspase-1 inhibition resulted in accumulation of sirtuin 1 in the ApoE(-/-) aorta, and sirtuin 1 inhibited caspase-1 upregulated genes via activator protein-1 pathway. CONCLUSIONS Our results demonstrate for the first time that early hyperlipidemia promotes EC activation before monocyte recruitment via a caspase-1-sirtuin 1-activator protein-1 pathway, which provides an important insight into the development of novel therapeutics for blocking caspase-1 activation as early intervention of metabolic cardiovascular diseases and inflammations.
Collapse
Affiliation(s)
- Ying Yin
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Xinyuan Li
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Xiaojin Sha
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Hang Xi
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Ya-Feng Li
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Ying Shao
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Jietang Mai
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Anthony Virtue
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Jahaira Lopez-Pastrana
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Shu Meng
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Douglas G Tilley
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - M Alexandra Monroy
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Eric T Choi
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Craig J Thomas
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Xiaohua Jiang
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Hong Wang
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.)
| | - Xiao-Feng Yang
- From the Centers for Metabolic Disease Research, Cardiovascular Research, Thrombosis Research (Y.Y., X.L., X.S., H.X., Y.-F.L., Y.S., J.M., A.V., J.L.-P., S.M., M.A.M., E.T.C., X.J., H.W., X.-F.Y.), Center for Translational Medicine (D.G.T.), Department of Pharmacology (Y.Y., X.L., X.S., H.X., Y.-F.L, Y.S., J.M., A.V., J.L.-P., S.M., D.G.T., X.J., H.W., X.-F.Y.), and Department of Surgery (M.A.M., E.T.C.), Temple University School of Medicine, Philadelphia, PA; and NIH Chemical Genomics Center, Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (C.J.T.).
| |
Collapse
|
13
|
Sheng M, Zhong Y, Chen Y, Du J, Ju X, Zhao C, Zhang G, Zhang L, Liu K, Yang N, Xie P, Li D, Zhang MQ, Jiang C. Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro. SCIENCE CHINA-LIFE SCIENCES 2014; 57:959-72. [PMID: 25218824 DOI: 10.1007/s11427-014-4742-y] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/16/2014] [Accepted: 08/20/2014] [Indexed: 01/11/2023]
Abstract
Ebola virus (EBOV) causes a highly lethal hemorrhagic fever syndrome in humans and has been associated with mortality rates of up to 91% in Zaire, the most lethal strain. Though the viral envelope glycoprotein (GP) mediates widespread inflammation and cellular damage, these changes have mainly focused on alterations at the protein level, the role of microRNAs (miRNAs) in the molecular pathogenesis underlying this lethal disease is not fully understood. Here, we report that the mi-RNAs hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p were induced in human umbilical vein endothelial cells (HUVECs) following expression of EBOV GP. Among the proteins encoded by predicted targets of these miRNAs, the adhesion-related molecules tissue factor pathway inhibitor (TFPI), dystroglycan1 (DAG1) and the caspase 8 and FADD-like apoptosis regulator (CFLAR) were significantly downregulated in EBOV GP-expressing HUVECs. Moreover, inhibition of hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p, or overexpression of TFPI, DAG1 and CFLAR rescued the cell viability that was induced by EBOV GP. Our results provide a novel molecular basis for EBOV pathogenesis and may contribute to the development of strategies to protect against future EBOV pandemics.
Collapse
Affiliation(s)
- MiaoMiao Sheng
- State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; Department of Biochemistry and Molecular Biology, Peking Union Medical College, Tsinghua University, Beijing, 100005, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Jia YY, Lu J, Huang Y, Liu G, Gao P, Wan YZ, Zhang R, Zhang ZQ, Yang RF, Tang X, Xu J, Wang X, Chen HZ, Liu DP. The involvement of NFAT transcriptional activity suppression in SIRT1-mediated inhibition of COX-2 expression induced by PMA/Ionomycin. PLoS One 2014; 9:e97999. [PMID: 24859347 PMCID: PMC4032329 DOI: 10.1371/journal.pone.0097999] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Accepted: 04/28/2014] [Indexed: 12/17/2022] Open
Abstract
SIRT1, a class III histone deacetylase, acts as a negative regulator for many transcription factors, and plays protective roles in inflammation and atherosclerosis. Transcription factor nuclear factor of activated T cells (NFAT) has been previously shown to play pro-inflammatory roles in endothelial cells. Inhibition of NFAT signaling may be an attractive target to regulate inflammation in atherosclerosis. However, whether NFAT transcriptional activity is suppressed by SIRT1 remains unknown. In this study, we found that SIRT1 suppressed NFAT-mediated transcriptional activity. SIRT1 interacted with NFAT, and the NHR and RHR domains of NFAT mediated the interaction with SIRT1. Moreover, we found that SIRT1 primarily deacetylated NFATc3. Adenoviral over-expression of SIRT1 suppressed PMA and calcium ionophore Ionomycin (PMA/Io)-induced COX-2 expression in human umbilical vein endothelial cells (HUVECs), while SIRT1 RNAi reversed the effects in HUVECs. Moreover, inhibition of COX-2 expression by SIRT1 in PMA/Io-treated HUVECs was largely abrogated by inhibiting NFAT activation. Furthermore, SIRT1 inhibited NFAT-induced COX-2 promoter activity, and reduced NFAT binding to the COX-2 promoter in PMA/Io-treated HUVECs. These results suggest that suppression of NFAT transcriptional activity is involved in SIRT1-mediated inhibition of COX-2 expression induced by PMA/Io, and that the negative regulatory mechanisms of NFAT by SIRT1 may contribute to its anti-inflammatory effects in atherosclerosis.
Collapse
Affiliation(s)
- Yu-Yan Jia
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
- State Key Laboratory of Medical Molecular Biology, Department of Medical Genetics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Jie Lu
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Yue Huang
- State Key Laboratory of Medical Molecular Biology, Department of Medical Genetics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Guang Liu
- State Key Laboratory of Medical Molecular Biology, Department of Medical Genetics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Peng Gao
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Yan-Zhen Wan
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Ran Zhang
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Zhu-Qin Zhang
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Rui-Feng Yang
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Xiaoqiang Tang
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Jing Xu
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Xu Wang
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
| | - Hou-Zao Chen
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
- * E-mail: (DPL); (HZC)
| | - De-Pei Liu
- State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China
- * E-mail: (DPL); (HZC)
| |
Collapse
|
15
|
MicroRNA-217 promotes angiogenesis of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and FOXO3A. PLoS One 2013; 8:e83620. [PMID: 24376725 PMCID: PMC3869804 DOI: 10.1371/journal.pone.0083620] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2013] [Accepted: 11/05/2013] [Indexed: 01/08/2023] Open
Abstract
Human cytomegalovirus(HCMV) infection has been shown to contribute to vascular disease through the induction of angiogenesis. However, the role of microRNA in angiogenesis induced by HCMV infection remains unclear. The present study was thus designed to explore the potential effect of miR-1217 on angiogenesis and to disclose the underlying mechanism in endothelial cells. We found that HCMV infection of endothelial cells(ECs) enhanced expression of miR-217 and reduced SIRT1 and FOXO3A protein level in 24 hours post infection(hpi). Transfection of miR-217 inhibitor not only depressed cellular migration and tube formation induced by HCMV infection, but also enhanced SIRT1 and FOXO3A protein expression. Additionally, luciferase assay confirmed that miR-217 directly targeted FOXO3A mRNA 3`UTR. Furthermore, pretreatment with resveratrol depressed motility and tube formation of HCMV-infected ECs, which could be reversed by SIRT1 siRNA. Similarly, delivery of FOXO3A overexpression lentivirus suppressed proliferative rate, migration and tube formation of HCMV-infected ECs, which reversed by transfection of FOXO3A siRNA. In summary, HCMV infection of endothelial cells induces angiogenesis by both of miR-217/SIRT1 and miR-217/FOXO3A axis.
Collapse
|
16
|
Tsai KL, Huang PH, Kao CL, Leu HB, Cheng YH, Liao YW, Yang YP, Chien Y, Wang CY, Hsiao CY, Chiou SH, Chen JW, Lin SJ. Aspirin attenuates vinorelbine-induced endothelial inflammation via modulating SIRT1/AMPK axis. Biochem Pharmacol 2013; 88:189-200. [PMID: 24345330 DOI: 10.1016/j.bcp.2013.12.005] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Revised: 11/24/2013] [Accepted: 12/03/2013] [Indexed: 12/20/2022]
Abstract
Vinorelbine (VNR), a semisynthetic vinca alkaloid acquired from vinblastine, is frequently used as the candidate for intervention of solid tumors. Nevertheless, VNR-caused endothelial injuries may lead a mitigative effect of clinical treatment efficiency. A growing body of evidence reveals that aspirin is a potent antioxidant and anti-inflammation drug. We investigated whether aspirin attenuate VNR-induced endothelial dysfunction. Human endothelial cells (EA.hy 926) were treated with VNR to cause endothelial inflammation. Western blotting, ROS assay, ELISA were used to confirm the anti-inflammatory effect of aspirin. We confirmed that VNR suppresses SIRT1 expression, reduced LKB1 and AMPK phosphorylation as well as enriched PKC activation in treated endothelial cells. Furthermore, the membrane translocation assay displayed that the levels of NADPH oxidase subunits p47phox and Rac-1 in membrane fractions of endothelial cells were higher in cells that had been treated with VNR for than in untreated cells. We corroborated that treatment of Aspirin significantly diminishes VNR-repressed SIRT1, LKB1 and AMPK phosphorylation and VNR-promoted NADPH oxidase activation, however, those findings were vanished by SIRT1 and AMPK siRNAs. Our data also shown that Aspirin represses VNR-activated TGF-beta-activated kinase-1 (TAK1) activation, inhibited the interaction of TAK1/TAK-binding protein1 (TAB1), suppressed NF-kappa B activation and pro-inflammatory cytokine secretion. We demonstrated a novel connection between VNR-caused oxidative damages and endothelial dysfunction, and provide further insight into the protective effects of aspirin in VNR-caused endothelial dysfunction.
Collapse
Affiliation(s)
- Kun-Ling Tsai
- Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
| | - Po-Hsun Huang
- Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Chung-Lan Kao
- Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; Department of Physical Medicine and Rehabilitation, Taipei, Taiwan
| | - Hsin-Bang Leu
- Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Yung-Hsin Cheng
- Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan
| | - Yi-Wen Liao
- Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan; Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Yi-Ping Yang
- Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan; Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Yueh Chien
- Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan; Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Chien-Ying Wang
- Department of Emergency Medicine, National Yang-Ming University, Taipei, Taiwan
| | - Chen-Yuan Hsiao
- Department of Surgery, National Yang-Ming University Hospital, Taipei, Taiwan
| | - Shih-Hwa Chiou
- Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan; Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan.
| | - Jaw-Wen Chen
- Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan; Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Shing-Jong Lin
- Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan.
| |
Collapse
|
17
|
Wang Y, Liu X, Wang W, Song W, Chen L, Fang Q, Yan X. The Expression of Inflammatory Cytokines on the Aorta Endothelia Are Up-regulated in Pinealectomized Rats. Inflammation 2013; 36:1363-73. [DOI: 10.1007/s10753-013-9676-1] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
18
|
Zhang S, Liu L, Wang R, Tuo H, Guo Y, Yi L, Wang J, Wang D. MiR-199a-5p promotes migration and tube formation of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and eNOS. Arch Virol 2013; 158:2443-52. [PMID: 23760629 DOI: 10.1007/s00705-013-1744-1] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2013] [Accepted: 04/22/2013] [Indexed: 01/10/2023]
Abstract
Human cytomegalovirus (HCMV) infection has been shown to contribute to vascular disease through the induction of angiogenesis. However, the role of microRNA in angiogenesis induced by HCMV infection remains unclear. The present study was thus designed to explore the potential effect of miR-199a-5p on angiogenesis and to investigate the underlying mechanism in endothelial cells. We found that HCMV infection of endothelial cells (ECs) enhanced expression of miR-199a-5p and reduced the SIRT1 protein level at 24 h postinfection (hpi). Transfection with miR-199a-5p mimics significantly suppressed SIRT1 protein expression and promoted cellular migration and tube formation induced by HCMV infection, which could be reversed by transfection with an miR-199a-5p inhibitor. Furthermore, pretreatment with resveratrol depressed motility and tube formation of HCMV-infected ECs, which could be reversed by SIRT1 siRNA. Finally, overexpression of miR-199a-5p decreased the level of eNOS modulated by SIRT1, an effect repressed by transfection with an miR-199a-5p inhibitor. In summary, HCMV infection of endothelial cells upregulates miR-199a-5p expression and enhances cell migration and tube formation through downregulation of SIRT1/eNOS by miR-199a-5p.
Collapse
Affiliation(s)
- Shanchao Zhang
- Department of Neurology, Beijing Friendship Hospital, Capital Medical University, NO.95 YongAn Road, Xuanwu District, Beijing, 100050, China
| | | | | | | | | | | | | | | |
Collapse
|